urbanbuzz / Shutterstock.com
Pfizer has apologised to UK-based healthcare providers for any confusion or increased workload following the English High Court’s decision on a patent infringement case centring on its epilepsy drug Lyrica (pregabalin).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Pfizer, Lyrica, NHS, second medical use patent, Actavis
